WW International, Inc. (WW)
NASDAQ (NMS) NASDAQ (NMS) Primary 
WW International (WW) Surges After Adding Semaglutide to Weight Loss Program
WW International (WW, Financial) experienced a significant stock price increase, soaring 20.7% to $1.40. Early trading saw the stock rise as much as 46.5%.
WW International (WW) Surges After Introducing Compounded Semaglutide to Weight Loss Plans
WW International (WW, Financial), a provider of weight loss solutions, experienced a significant stock movement with an initial surge of over 46.5%, which later narrowed to around a 25% increase, reaching $1.45. This follows a nearly 47% rise in the previous trading session.
WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering
Shares of WW International (WW), better known as WeightWatchers, jumped nearly 25% Tuesday when the dieting services company announced it is offering a copycat version of blockbuster weight-loss drugs.
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs.
WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs
WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.
WeightWatchers CEO Sima Sistani is leaving the company
WeightWatchers CEO Sima Sistani is leaving the company after two and a half years. During that time, the company has radically altered its business model to stay competitive in the Ozempic era.
WW International: There May Never Be A Resurrection
WW International, Inc. stock has lost almost 80% of its value since my previous article in March 2023, which I published soon after the company announced the Sequence acquisition. Expansion into clinical services poses risks of cannibalization and increased competition for WW International's core weight loss business. The strategic shift towards digital subscriptions and clinical services may limit WW International's potential for long-term competitive advantages and growth.
WW International, Inc. (WW) Q2 2024 Earnings Call Transcript
WW International, Inc. (NASDAQ:WW ) Q2 2024 Earnings Call August 1, 2024 8:30 AM ET Company Participants Corey Kinger - Vice President, Investor Relations Sima Sistani - Chief Executive Officer Heather Stark - Chief Financial Officer Conference Call Participants Jack Wallace - Guggenheim Securities Henry Carr - UBS Nathan Feather - Morgan Stanley Alex Fuhrman - Craig-Hallum Stephanie Davis - Barclays Karru Martinson - Jefferies Operator Welcome to the WW International's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I'd now like to turn the call over to your host, Corey Kinger, VP Investor Relations.
WW International (WW) Reports Q2 Loss, Lags Revenue Estimates
WW International (WW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.04 per share a year ago.
WW International's stock falls toward a fresh record low after disappointing results, lowered outlook
Shares of WW International Inc., formerly known as Weight Watchers, dropped 1.9% into record-low territory, after the weight management company reported disappointing second-quarter results, lowered its full-year outlook and announced a restructuring plan. Net income fell to $23.3 million, or 29 cents a share, from $50.8 million, or 65 cents a share, in the same period a year ago.
